Peter Attia MD - Why are pharmaceutical drugs so expensive in the US? | Peter Attia and Saum Sutaria
The video begins by highlighting the significant portion of U.S. healthcare spending that goes towards drugs, noting that Americans pay much more for drugs compared to other countries. The discussion then shifts to Pharmacy Benefit Managers (PBMs), which act as intermediaries between pharmaceutical companies, insurers, and pharmacies. PBMs were originally created to manage the complexity of drug choices and costs, but their role has evolved into a complex payment system that can influence drug prices through rebate structures. An example is given where a PBM demanded a pharmaceutical company to triple the price of a drug to include it in their formulary, promising to compensate through rebates. This system has led to a lack of transparency and incentives that do not necessarily align with lowering drug prices. The video concludes by pointing out the disconnect between healthcare providers and the actual cost of drugs, contributing to unnecessary expenses in the healthcare system.
Key Points:
- Drugs account for a significant portion of U.S. healthcare spending, with Americans paying more for drugs than other countries.
- Pharmacy Benefit Managers (PBMs) were created to manage drug costs and choices but have evolved into complex intermediaries that can drive up drug prices.
- The rebate system used by PBMs can create incentives for higher drug prices, as illustrated by an example where a PBM required a drug price increase to include it in their formulary.
- There is a lack of transparency in the drug pricing system, making it difficult for healthcare providers to consider drug costs when prescribing.
- The current system contributes to unnecessary healthcare costs due to misaligned incentives and opaque pricing structures.